# Utidelone Plus Bevacizumab for Advanced Breast Cancer With Brain Metastases

> **NCT05357417** · PHASE2 · UNKNOWN · sponsor: **Henan Cancer Hospital** · enrollment: 100 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** utidelone
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT05357417
- **Lead sponsor:** Henan Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-04-29
- **Primary completion:** 2024-05
- **Final completion:** 2024-05
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2022-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05357417

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05357417, "Utidelone Plus Bevacizumab for Advanced Breast Cancer With Brain Metastases". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05357417. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*